Pfizer Executive On Paxlovid’s Development And Design Journey

A senior Pfizer Inc. executive outlined, at a recent summit, some of the defining aspects of COVID-19 treatment Paxlovid’s (nirmatrelvir and ritonavir) development journey from first synthesis to first emergency use authorization (EUA). It was strikingly fast – speed with urgency and without cutting any corners for safety, as the executive put it.

Addressing the Organization of Pharmaceutical Producers of India (OPPI) summit, Pfizer’s senior vice president and chief scientific officer, bacterial vaccines and hospital, Dr Annaliesa Anderson, indicated that the oral antiviral had a four-month discovery phase, where the US company utilized its experience in “digital